Skip to main content
Equibles
BVS logo

BVS · Bioventus Inc. · Webcasts, Transcripts & Audio

Track BVS — free

Use BVS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BVS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.96 -0.08 (-0.53%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$1.26B
Shares
84.09M
Volume · Oct 23 387.05K Avg daily vol (3M) 583.02K

Bioventus Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Bioventus Inc. (BVS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-08-05
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Confident tone Pain and Stimulation (P&S / PNS) PRP (platelet-rich plasma) momentum Surgical business acceleration
Revenue
$153.21M
▲ 3.8% YoY
Diluted EPS
$0.47
▲ 327.3% YoY
Gross margin
69.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Bioventus Inc. (BVS) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript
Confident tone Revenue growth and investment acceleration PNS business ramp-up Cash flow and balance sheet
Revenue
$132.09M
▲ 6.6% YoY
Diluted EPS
$0.04
Gross margin
68.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Bioventus Inc. (BVS) Q4 2025 Earnings Call Transcript
Confident tone PNS growth driver Ultrasonics business Profitability expansion
Revenue
$157.90M*
▲ 2.8% YoY
Gross margin
68.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Bioventus Inc. (BVS) Q3 2025 Earnings Call Transcript
Confident tone Organic revenue growth and portfolio momentum Profitability and EBITDA margin expansion Pain treatments and surgical solutions (P&S) core business
Revenue
$138.65M
▼ 0.2% YoY
Diluted EPS
$0.05
Gross margin
68.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript
Positive tone Full-year guidance reiteration Ultrasonics growth Tariffs and FX headwinds
Revenue
$147.66M
▼ 2.4% YoY
Diluted EPS
$0.11
Gross margin
69.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript
Positive tone Profitability and Cash Flow Pain Treatments / DUROLANE Surgical Solutions / Ultrasonics
Revenue
$123.88M
▼ 4.3% YoY
Diluted EPS
$-0.04
Gross margin
67.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript
Confident tone 2024 Financial Performance International Expansion Exogen Restorative Therapy Turnaround
Revenue
$153.64M*
▲ 13.5% YoY
Gross margin
66.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript
Confident tone Profitability / Margin Expansion Revenue Growth Surgical Solutions / Ultronics
Revenue
$138.96M
▲ 15% YoY
Diluted EPS
$-0.08
Gross margin
67.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Bioventus Inc. (BVS) Q2 2024 Earnings Call Transcript
Confident tone Liquidity and leverage reduction Revenue growth and double-digit organic performance Surgical Solutions and Ultrasonics franchise
Revenue
$151.22M
▲ 10.3% YoY
Diluted EPS
$-0.40
Gross margin
68.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Bioventus Inc. (BVS) Q1 2024 Earnings Call Transcript
Confident tone Surgical Solutions momentum HA / Durolane growth Guidance and outlook
Revenue
$129.46M
▲ 8.7% YoY
Diluted EPS
$-0.08
Gross margin
68.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
Bioventus Inc. (BVS) Q4 2023 Earnings Call Transcript
Positive tone Cash flow and leverage Revenue growth acceleration HA / Pain Treatment portfolio (DUROLANE, GELSYN, SUPARTZ)
Revenue
$135.42M*
▲ 7.6% YoY
Gross margin
63.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Bioventus Inc. (BVS) Q3 2023 Earnings Call Transcript
Revenue
$120.79M
▼ 6.1% YoY
Diluted EPS
$-0.12
Gross margin
65.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Bioventus Inc. (BVS) Q2 2023 Earnings Call Transcript
Revenue
$137.07M
▼ 2.3% YoY
Diluted EPS
$-0.06
Gross margin
65.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-16
Bioventus Inc. (BVS) Q1 2023 Earnings Call Transcript
Revenue
$119.06M
▲ 1.5% YoY
Diluted EPS
$-2.24
Gross margin
62.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-31
Bioventus Inc. (BVS) Q4 2022 Earnings Call Transcript
Revenue
$125.83M*
▼ 3.5% YoY
Gross margin
59.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Bioventus Inc. (BVS) Q3 2022 Earnings Call Transcript
Revenue
$128.66M
▲ 18.2% YoY
Diluted EPS
$-1.76
Gross margin
65.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Bioventus Inc. (BVS) Q2 2022 Earnings Call Transcript
Revenue
$140.33M
▲ 27.8% YoY
Diluted EPS
$-0.11
Gross margin
68.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Bioventus Inc. (BVS) Q1 2022 Earnings Call Transcript
Revenue
$117.29M
▲ 43.4% YoY
Diluted EPS
$-0.19
Gross margin
64.5%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Bioventus Inc. (BVS) Q4 2021 Earnings Call Transcript
Revenue
$130.41M*
▲ 32.3% YoY
Gross margin
67.3%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Bioventus Inc. (BVS) Q3 2021 Earnings Call Transcript
Revenue
$108.89M
▲ 26.8% YoY
Diluted EPS
$-0.03
Gross margin
72.6%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Bioventus Inc. (BVS) Q2 2021 Earnings Call Transcript
Revenue
$109.82M
▲ 89.3% YoY
Diluted EPS
$-0.10
Gross margin
69.5%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Bioventus Inc. (BVS) Q1 2021 Earnings Call Transcript
Revenue
$81.78M
▲ 4% YoY
Diluted EPS
$-0.02
Gross margin
72.8%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Bioventus Inc. (BVS) Q4 2020 Earnings Call
Revenue
$98.59M*
Gross margin
74.5%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 webcasts
Key facts CIK 1665988 CUSIP 09075A108 13F (30d) 21 filings 21 filers Visit website Investor relations